Akero Therapeutics, Inc. logo

Akero Therapeutics, Inc.

NASDAQ:AKRO

Overview | Financials
Company Name Akero Therapeutics, Inc.
Symbol AKRO
Currency USD
Price 26.41
Market Cap 1,833,667,428
Dividend Yield 0%
52-week-range 11.25 - 53.77
Industry Biotechnology
Sector Healthcare
CEO Dr. Andrew Cheng M.D., Ph.D.
Website https://www.akerotx.com

An error occurred while fetching data.

About Akero Therapeutics, Inc.

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates,

Related Stocks

Theseus Pharmaceuticals, Inc. logo

Theseus Pharmaceuticals, Inc.

THRX

4.065 USD

Talaris Therapeutics, Inc. logo

Talaris Therapeutics, Inc.

TALS

2.72 USD

Aadi Bioscience, Inc. logo

Aadi Bioscience, Inc.

AADI

1.83 USD

Eiger BioPharmaceuticals, Inc. logo

Eiger BioPharmaceuticals, Inc.

EIGR

1.725 USD

Radius Health, Inc. logo

Radius Health, Inc.

RDUS

14.68 USD

Icosavax, Inc. logo

Icosavax, Inc.

ICVX

15.31 USD

Financials

Numbers are in millions USD

Numbers are in millions USD